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Cardiac arrest is deﬁned as the sudden cessation of spontaneous ventilation and circulation. Within 15 seconds of cardiac arrest,
the patient loses consciousness, electroencephalogram becomes ﬂat after 30 seconds, pupils dilate fully after 60 seconds, and
cerebral damage takes place within 90–300 seconds. It is essential to act immediately as irreversible damage can occur in a
short time. Cardiopulmonary resuscitation (CPR) is an attempt to restore spontaneous circulation through a broad range of
interventions which are early deﬁbrillation, high-quality and uninterrupted chest compressions, advanced airway interventions,
and pharmacological interventions. Drugs should be considered only after initial shocks have been delivered (when indicated)
and chest compressions and ventilation have been started. During cardiopulmonary resuscitation, no speciﬁc drug therapy has
been shown to improve survival to hospital discharge after cardiac arrest, and only few drugs have a proven beneﬁt for short-term
survival. This paper reviews current pharmacological treatment of cardiac arrest. There are three groups of drugs relevant to the
management of cardiac arrest: vasopressors, antiarrhythmics, and other drugs such as sodium bicarbonate, calcium, magnesium,
atropine, ﬁbrinolytic drugs, and corticosteroids.
1.Introduction
Cardiac arrest constitutes a major health problem with dis-
mal prognosis. Cardiac arrest may be caused either by asys-
tole, pulseless electrical activity (PEA), pulseless ventricular
tachycardia (VT), or ventricular ﬁbrillation (VF) [1].
Data from 37 communities in Europe indicate that the
annual incidence of Emergency Medical Services- (EMS-)
treated, out-of-hospital, cardiopulmonary arrest for all
rhythms is 38 per 100,000 population [2]. The annual inci-
dence of EMS-treated VF arrest is 17 per 100,000. Survival
to hospital discharge is 10.7% for all-rhythm and 21.2% for
VF cardiac arrest. Recent data from 10 North American sites
are consistent with these ﬁgures: median rate of survival to
hospital discharge was 8.4% after EMS-treated cardiac arrest
from any rhythm and 22.0% after VF [3].
In-hospitalcardiacarrestoccursin1to5per1000patient
admissions [4]. The American Heart Association’s National
Registry of cardiopulmonary resuscitation (CPR) indicate
that survival to hospital discharge after in-hospital cardiac
arrest is 17.6% (for all rhythms) [5]. The initial rhythm is VF
or pulseless-VT in 25% of cases and, of these, 37% leave the
hospital alive. After PEA or asystole, 11.5% survive to hos-
pital discharge.
Multistage algorithms have been developed for CPR. In
the algorithm for CPR, cardiac arrest rhythms are divided
into two groups: shockable rhythms (VF/pulseless VT) and
nonshockable rhythms (asystole, PEA).
The main diﬀerence in the treatment of these groups is
the need for attempted deﬁbrillation in those patients with
VF/pulseless VT. Subsequent actions, including high-quality
chestcompressionswithminimalinterruptions,airwayman-
agementandventilation,venousaccess,administrationofre-
suscitation drugs, the identiﬁcation and correction of revers-
ible factors (hypoxia, hypovolaemia, hypothermia, hypo-/
hyperkalaemia (4Hs), thrombosis-coronary or pulmonary,
tamponade, toxins, tension pneumothorax (4Ts)), and the
use of therapeutic hypothermia in comatose survivors are
common to both groups [6].2 Emergency Medicine International
We emphasize the importance of high-quality CPR (in-
cluding chest compressions of adequate rate and depth, al-
lowing complete chest recoil after each compression, min-
imizing interruptions in chest compressions and avoiding
excessiveventilation),earlydeﬁbrillation,andtheuseofther-
apeutic hypothermia in comatose survivors.
In any case, during CPR, vascular access, drug delivery,
and advanced airway management should not cause signif-
icant interruptions in chest compressions or delay deﬁbrilla-
tion.
In this paper, we summarize current experimental and
clinical data on the eﬃcacy and safety of drugs during
CPR (vasopressors, antiarrhythmics, and other drugs such as
sodium bicarbonate, calcium, magnesium, atropine, ﬁbrino-
lytic drugs, and corticosteroids).
2.Vasopressors
Cardiacarrestischaracterizedbyglobalischemia,tissuehyp-
oxia, and acidosis. CPR aims to improve the oxygen supply-
demand ratio, in order to reverse tissue hypoxia.
Vasopressors are drugs that have a predominantly vaso-
constrictive action on the peripheral vasculature, both arte-
rial and venous. These drugs are used, during cardiac arrest,
primarily to increase coronary and cerebral perfusion pres-
sures and ﬂows and thus facilitate ROSC.
Furthermore, during cardiac arrest, there is insuﬃcient
release of endogenous vasoconstrictors as part of the stress
response, and this is another reason for using vasopressors.
To date, there is no placebo-controlled study that shows that
the routine use of any vasopressor at any stage during cardiac
arrest increases neurologically intact survival to hospital dis-
charge. However, there is evidence that vasopressors are as-
sociated with an increased rate of ROSC.
Epinephrine and vasopressin are the most commonly
studied vasopressors in cardiac arrest. Historically, epineph-
rine has been used for the treatment of cardiac arrest for over
100 years [7]. However, vasopressin has been the focus of
considerable research eﬀort and has gained some popularity
asapotentialadjunctoralternativetoepinephrine.Thereare
no alternative vasopressors (norepinephrine, phenylephrine)
with proven survival beneﬁt relative to epinephrine [8, 9].
2.1. Epinephrine. Epinephrine is a powerful agonist at both
α-andβ-AdrenergicReceptors.Stimulationoftheβ-receptor
activates Gs-proteins, which in turn activate adenyl cyclase
and thus lead to the generation of circular adenosine mo-
nophosphate (cAMP). In cardiac myocytes, this leads to
increased intracellular Ca2+ concentration and contractility
(inotropic eﬀect). The stimulation of the β-receptor can also
cause positive chronotropic eﬀects (increased heart rate) and
dromotropic eﬀects (augmented conduction). In contrast,
α1-receptor stimulation results in the activation of phospho-
lipase C, increased formation of inositol phosphates (IP3,
IP4) and diacyl glycerol, and smooth muscle contraction
(Figure 1).
Epinephrine has been used for the treatment of cardiac
arrestmostlyforitsα-adrenergiceﬀectswhichcausesystemic
vasoconstriction, and increase coronary and cerebral per-
Figure 1: Schematic representation of the action of epinephrine
on intracellular calcium in myocytes. ATP: adenosine triphosphate,
cAMP: cyclic adenosine monophosphate, Gs: G protein com-
plex, IP: inositol phosphate, PIP2: phosphoinositol diphosphate,
(adapted from OH’S intensive care manual).
fusion pressures. The beta-adrenergic actions of adrenaline
(inotropic, chronotropic) may increase coronary and cere-
bralbloodﬂow,butmayalsohavecatastrophiceﬀectssuchas
the increase of myocardial oxygen consumption, ventricular
arrhythmias(particularlywhenthecardiactissueisacidotic),
transient hypoxemia secondary to attenuation of hypoxic
pulmonary vasoconstriction, and consequent increase in
intrapulmonary, arteriovenous shunting, impaired microcir-
culation [10], and heart failure after ROSC [11]. Despite
these deleterious eﬀects and the limited evidence of beneﬁt
from the use of epinephrine during cardiac arrest, the
improved short-term survival documented in some studies
[12, 13] supports its continued use in cardiac arrest.
There are few data on the pharmacokinetics of epi-
nephrine during CPR. In animal studies, peak plasma con-
centrations occur at about 90 seconds after a peripheral in-
jection. The optimal dose of epinephrine is not known.
A meta-analysis of studies comparing standard- (1mg or
0.02mg/kg) versus high dose (5–15mg) epinephrine (3199
patientsreceivedhigh-doseand3140patientsreceivedstand-
ard dose), demonstrated improved ROSC in the high dose
epinephrine group but failed to demonstrate any long-
term survival beneﬁt of the high and/or escalating dose of
epinephrine [14]. Considering these results, Babbs et al. [15]
concluded that a high initial dose of epinephrine in cardiac
arrest may increase coronary perfusion pressures (CPP) and
ROSC, but may also exacerbate postresuscitation myocardial
dysfunction and cause harm. They concluded that high dos-
es of epinephrine do not improve long-term survival and
neurological outcome. Laboratory studies also documented
adverse eﬀects of high-dose epinephrine when given during
CPR, including postresuscitation hyperadrenergic state [16],
m y o c a r d i a ln e c r o s i s[ 17], worsened postarrest cardiomyopa-
thy [18], and greater early mortality relative to the standard
dose [19].Emergency Medicine International 3
In view of the above, current guidelines (2010) for ALS
recommend a standard dose of 1mg of epinephrine (IV/IO)
every 3 to 5 minutes during adult cardiac arrest (Class IIb,
LOE A). Higher doses may be indicated to treat speciﬁc pro-
blems, such as a beta-blocker or calcium channel blocker
overdose [6].
If the initial arrest rhythm is PEA or asystole, the admin-
istration of epinephrine is recommended as soon as vascular
accessisobtained.ForVForpulselessVT,theadministration
of epinephrine is recommended, after the third shock, and
upon the resumption of chest compressions [20].
2.2. Vasopressin. The potentially catastrophic beta-eﬀects of
epinephrine led to the exploration of alternative vasopres-
sors. In survivors of cardiac arrest endogenous vasopressin
levels are higher than in nonsurvivors [21].
Arginine vasopressin(AVP)—ahypothalamichormone—
also known as antidiuretic hormone is a nonapeptide, that
is, a 9 amino acid peptide. AVP is released from the posterior
pituitarymostlywhenplasmaosmolalityisincreasedorplas-
ma volume is reduced.
It acts via speciﬁc G-protein-coupled receptors. Three
speciﬁc vasopressin receptors (V1,2,3) are responsible for vas-
opressin’s pharmacological eﬀects. V1 receptors are located
in vascular smooth muscle and mediate vasoconstriction,
V2 receptors are located in the distal convoluted tubules
and medullary collecting ducts and mediate antidiuresis, V3
receptors are located in the anterior hypophysis and pan-
creatic isles and seem to aﬀect insulin secretion, facilitate ad-
renocorticotropin release, and modulate memory, body tem-
perature, and blood pressure.
Vasopressin is metabolized by vasopressinases in the liver
andkidneyanditshalf-lifeis10–35min.Ithasseveraladvan-
tages over epinephrine in CPR because it improves cere-
bral and myocardial blood ﬂow via V1-receptor mediated
vasoconstriction, without the unwanted beta-eﬀects of epi-
nephrine. Also, in contrast to epinephrine, vasopressin’s vas-
oconstrictive eﬀect is preserved during hypoxia and severe
acidosis. In addition, the risk of postresuscitation myocardial
dysfunction is lower [22].
TheeﬀectofvasopressinduringCPRhasbeenextensively
investigated in laboratory models. Animal studies demon-
strated that vasopressin versus epinephrine increased blood
ﬂow in vital organs [23], improved cerebral oxygen delivery
[24], and increased the probability of restoring spontaneous
circulation [25] and neurologic outcome [26], as compared
with epinephrine. The combination of vasopressin and epi-
nephrine tripled coronary perfusion pressure versus either
epinephrine or vasopressin alone, in a pig model of pro-
longed asphyxia [27]. In contrast to the animal studies, hu-
man trials showed no clear beneﬁt of vasopressin over epi-
nephrine in the treatment of cardiac arrest.
Three randomised controlled trials [28–30]a n dam e t a -
analysis [31] demonstrated no diﬀerence in outcomes
(ROSC, survival to hospital discharge, or neurological out-
come) between vasopressin and epinephrine used as ﬁrst line
vasopressorincardiacarrest.Similarly,therewasnoevidence
of harm from the use of vasopressin given during CPR.
Lindner et al. [28] conducted a randomized controlled
trial involving 40 patients with out-of-hospital VF that was
unresponsive to deﬁbrillation. Vasopressin versus epineph-
rine increased 24-hour survival, but there was no between-
group diﬀerence in the other outcomes (i.e., ROSC, survival
on hospital admission, survival to hospital discharge, and
neurological outcome).
Stiell et al. [29] conducted a randomized controlled trial
involving 200 patients with in-hospital cardiac arrest and
showed no statistically signiﬁcant diﬀerences in outcomes
(survival to 1 hour, survival to hospital discharge and neu-
rological outcome) between vasopressin and epinephrine.
Wenzel et al. [30]c o n d u c t e dal a r g e ,m u l t i c e n t e r ,r a n -
domized, controlled study involving 1219 patients with out-
of-hospital cardiac arrest and showed no overall statisti-
cally signiﬁcant diﬀerences in outcomes (ROSC, survival
to hospital discharge, and neurological outcome) between
the vasopressin and epinephrine groups. Subgroup analyses
showed that the use of vasopressin in patients with asystole
was associated with higher rates of hospital admission and
survival to hospital discharge.
Two more recent, randomized, controlled trials [32,
33] showed no diﬀerence in outcomes (ROSC, survival to
hospital discharge, and neurological outcome) when com-
paring epinephrine in combination with vasopressin versus
epinephrine alone in cardiac arrest. In the large clinical trial
in France, a total of 1442 patients with out-of-hospital car-
diac arrest received a combination of epinephrine and vaso-
pressin, and 1452 received epinephrine alone. The authors
concluded that compared with epinephrine alone, the com-
bination of vasopressin and epinephrine during ALS for out-
of-hospital cardiac arrest does not improve outcome [33].
A recent study reported that the combination of vaso-
pressin and epinephrine during cardiopulmonary resuscita-
tion increased end-tidal carbon dioxide and mean arterial
blood pressure [34]. This improvement in these surrogate
measures of vital-organ perfusion may have been the mech-
anism responsible for the subsequent, observed increase in
short-term survival.
Mentzelopoulos et al. [35] conducted a single-center,
prospective, randomized, double-blind, placebo-controlled
trial, involving 100 patients with in hospital refractory car-
diac arrest and studied the eﬃcacy of combined vasopressin-
epinephrine during CPR with corticosteroid supplemen-
tation during and after CPR, compared with epinephrine
alone, without corticosteroid supplementation. The authors
concluded that compared with epinephrine alone, the com-
bination of vasopressin and epinephrine with corticosteroid
supplementation during and after CPR improves ROSC and
survival to hospital discharge.
In view of the above, the American Heart Association
current guidelines (2010) for ALS recommend that vaso-
pressin (40 units) may replace either the ﬁrst or the second
dose of epinephrine in the treatment of cardiac arrest (Class
IIb, LOE A).
3.Antiarrhythmics
Antiarrhythmic drugs produce pharmacologic eﬀects by
blocking sodium, potassium, and calcium ion channels
present in the heart. The cardiac action potential is the result4 Emergency Medicine International
of multiple inward and outward ion currents with speciﬁc
ion channels responsible for each of its ﬁve phases. The ef-
fects of antiarrhythmic drugs on the action potential and ef-
fective refractory period of the cardiac action potential
determine the clinical eﬀect of these drugs.
Lidocaine has traditionally been the antiarrhythmic drug
of choice for the treatment of shock-resistant VF and for
the prevention of VF recurrence after out of hospital cardiac
arrest[36].However,amiodaronehasbeenshowntoincrease
survival to hospital admission after out of hospital cardiac
arrest when compared with placebo or lidocaine and is now
recommended as the antiarrhythmic drug of choice for the
treatment of refractory VF/VT. Lidocaine is indicated in
refractory VF/VT when amiodarone is unavailable.
3.1. Amiodarone. Amiodarone is a potent antiarrhythmic
agent with a complex electrophysiological and pharmaco-
logical proﬁle. It is primarily a Vaughan Williams Class III
agent; it acts by inhibiting the inward potassium current.
It also blocks sodium and calcium channels and has antia-
drenergic eﬀects(noncompetitive blockadeofalphaandbeta
receptors). It prolongs the duration of the action potential,
increases the refractoriness of all cardiac tissue, and also pro-
longs the QT interval. Amiodarone is eﬀective in suppressing
both supraventricular and ventricular tachyarrhythmias.
Amiodarone exerts important cardiovascular eﬀects.
It dilates coronary arteries and increases coronary blood
supply, and it causes peripheral arterial vasodilation and de-
creases systemic vascular resistance. Hypotension and brady-
cardia are the major acute adverse eﬀects from amiodarone.
They are related to the rate of infusion and to the solvent
(polysorbate 80 and benzyl alcohol) which causes histamine
release [37]. These adverse eﬀects can be prevented by slow-
ing the rate of infusion and can be treated with ﬂuids and/or
inotropic drugs. Recently, a new aqueous formulation of in-
travenous amiodarone, that is, relatively free from these
adverse eﬀects was approved for use in the United States
[38]. An animal study on refractory VF noted that the com-
bination of amiodarone and epinephrine administered to-
gether produced haemodynamics as good as epinephrine
alone [39].
In two randomized, double-blind clinical trials, amio-
darone has been shown to be superior to both placebo and
lidocaine in improving survival to hospital admission for
patients with out-of-hospital refractory VF/pulseless VT [40,
41].
The ARREST trial involved 504 patients randomized to
receive either amiodarone (300mg bolus after the failure of
three shocks and administration of epinephrine) or placebo;
44% of amiodarone-treated patients and 34% of placebo-
treated patients survived to hospital admission (P = 0.03)
[40].
The ALIVE trial involved 347 patients randomized to
either amiodarone (initial bolus dose of 5mg/Kg followed,
if needed, by a second dose of 2.5mg/Kg) or lidocaine
(initial bolus dose of 1.5mg/Kg, repeated once, if needed);
more patients treated with amiodarone survived to hospital
admission, compared with patients treated with lidocaine
(23% versus 12%, P<0.005) [41].
In view of the above, the American Heart Association
current guidelines (2010) for ALS recommend that amiodar-
one may be considered for refractory VF/pulseless VT (Class
IIb, LOE B), with an initial dose of 300mg, which can be
followed by one dose of 150mg.
3.2. Lidocaine. Lidocaine, long considered an important an-
tiarrhythmicdrugforrefractoryVF/pulselessVT,isnowrele-
gated to a second-choice option. It decreases ventricular
automaticity. It also has a sodium channel-blocking eﬀect,
which is increased in myocardial ischaemia. Signs of lido-
caine toxicity such as paraesthesia, confusion, and convul-
sions may occur in a dose-related manner. It is considered
that a safe dose of lidocaine must not exceed 3mg/Kg over
the ﬁrst hour of administration.
In refractory VF/pulseless VT, lidocaine may be con-
sidered if amiodarone is not available (Class IIb, LOE B).
The initial dose is 100mg (1–1.5mg/Kg) with additional bo-
l u s ( e s )o f5 0m gu pt ot h em a x i m u md o s eo f3m g / K g .
3.3. Magnesium. Magnesium is a cofactor for many enzyme
systems,includingthemyocardialsodium/potassiumATPase.
It is an emerging antiarrhythmic agent that may be best clas-
siﬁed as a sodium/potassium pump agonist. Magnesium has
many electrophysiological eﬀects, including blocking atrial L
and T type calcium channels. It prolongs both atrial refrac-
tory period and conduction, inhibits potassium entry, and
suppresses ventricular after-depolarizations.
The electrophysiological eﬀects of magnesium are more
potent in the presence of increased extracellular potassium,
and thus the usefulness of magnesium seems to be greater in
the presence of ischemia, where loss of potassium from the
cell is a major consequence.
Intravenous magnesium sulphate is indicated in torsades
de pointes associated with prolonged QT interval, ventric-
ular, or supraventricular tachycardia associated with hypo-
magnesaemia, and digoxin toxicity.
In two studies, magnesium sulphate has been shown to
facilitate termination of torsades de pointes associated with
a prolonged QT interval [42, 43] .Ab o l u sd o s eo f1t o2g
of magnesium sulphate diluted in 10mL of 5% dextrose in
water is recommended (Class IIb, LOE C).
Itwasassumedthatmagnesiummightexertbeneﬁcialef-
fects in cardiac arrest, mainly due to its antiarrhythmic and
calcium-channel blocking properties [44]. However, three
randomised controlled trials [45–47], have failed to demon-
strate any beneﬁt of giving magnesium routinely during
cardiac arrest.
In view of the above, the American Heart Association
guidelines for ALS (2010) do not recommend the routine
administration of magnesium sulfate in cardiac arrest (Class
III, LOE A), unless torsades de pointes is present.
4.Other Drugs
There is no evidence that the routine administration of other
drugs such as atropine, calcium, sodium bicarbonate, or
ﬁbrinolytic drugs during cardiac arrest increases survival toEmergency Medicine International 5
hospital discharge. The administration of these drugs may be
considered in speciﬁc cases of cardiac arrest.
4.1. Atropine. Atropine is an anticholinergic drug, an ester
of tropic acid and tropine. It blocks muscarinic acetylcholine
receptors, and, thus, it blocks the eﬀect of the vagus nerve
on both the sinoatrial node and the atrioventricular node,
and thus increases sinus node automaticity and facilitates
atrioventricular conduction.
Atropine is administered in doses of 0.6–3.0mg IV to
counteract bradycardia in the presence of hypotension and
to prevent the bradycardia associated with vagal stimulation.
Side eﬀects of atropine are dose-related. A dose of ≤0.5mg
may produce an agonist action with a resulting bradycardia.
The side eﬀects of atropine are delirium, tachycardia, in-
crease in cardiac work and ventricular arrhythmias, coma,
hot skin, blurred vision, and/or urinary retention, pupillary
muscle dilation.
The eﬀect of atropine during CPR has been questioned.
In 1979, Brown et al. [48] noted the possible role of the
parasympatheticnervoussystemincardiacarrestandreport-
ed that atropine is beneﬁcial during cardiac arrest. Due to
this report, the AHA included atropine in the treatment of
asystole.
In 1981, Coon et al. [49] failed to demonstrate any ben-
eﬁt from the administration of atropine in out-of-hospital
asystole or PEA.
Stueven and colleagues [50] reported that patients who
received atropine had better resuscitation rates and better
survival when atropine was given late during ALS. Consid-
ering that there was no record of the rhythm at this point,
we cannot exclude the possibility that patients had begun to
regain a pulse when atropine was given. Recent studies have
failed to show any beneﬁt from the use of atropine in out of
hospital or in hospital cardiac arrest [51–53].
Atropine is no longer included in the ALS algorithm.
4.2. Calcium. Calcium ions are involved in cellular excita-
tion, excitation-contraction coupling, and muscle contrac-
tion in cardiac, skeletal, and smooth muscle cells. Increased
extracellular calcium increases intracellular calcium concen-
trations,andtheforceofcontractionofcardiacmyocytesand
vascular smooth muscle cells.
There is a direct correlation between duration of resus-
citation, low serum ionized calcium levels and mortality.
However, high plasma calcium concentration after exoge-
nous calcium injection may promote myocardial damage
and impair neurological recovery. Improved survival was
suggested by case reports of calcium use in children during
cardiac surgery [54]. However, studies of calcium during
cardiac arrest failed to demonstrate any beneﬁcial eﬀect on
survival [55–57].
Calciumisnotrecommendedforthetreatmentofcardiac
arrest (Class III, LOE B). Administration of calcium during
resuscitation is considered only in speciﬁc circumstances
such as hyperkalaemia, hypocalcaemia, and overdose of
calcium channel-blocking drugs.
4.3. Sodium Bicarbonate. During cardiac arrest and CPR,
combined respiratory and metabolic acidosis arises from the
carbon dioxide retention as pulmonary gas exchange ceases
and from the reduction in cellular oxygen availability which
leadstothedevelopmentofanaerobicmetabolismwithlactic
acidosis.Severeacidosisinhibitsmyocardialcontractilityand
also reduces the responsiveness to catecholamines.
Before1986,sodiumbicarbonatewasroutinelyuseddur-
ing CPR, even without knowledge of the patient’s acid-base
status.Thispracticewaschangedduetothepotentialadverse
eﬀects of buﬀer therapy and due to the clinical studies that
failed to demonstrate any advantage of using sodium bicar-
bonate during cardiac arrest [58–60].
Buﬀer therapy during CPR can exacerbate intracellular
acidosis since it generates carbon dioxide that freely diﬀuses
across cellular membranes. It is estimated that 1mEq/kg of
sodium bicarbonate, given intravenously, produces approxi-
mately 180mL of carbon dioxide, requiring a transient dou-
bling of alveolar ventilation to prevent hypercarbia. Sodium
bicarbonate during CPR may also cause hypernatraemia and
hyperosmolality to an already compromised circulation and
brain, metabolic alkalosis and a leftward shift in the oxygen
haemoglobin saturation curve, which further inhibits the
releaseofoxygentothetissues.Mildacidaemiacausesvasod-
ilation and thus increases cerebral blood ﬂow.
The routine administration of sodium bicarbonate is not
recommended in patients with cardiac arrest (Class III, LOE
B). Sodium bicarbonate may be given in cases of tricyclic
antidepressant overdose and hyperkalaemia.
4.4. Fibrinolytic Drugs. Thrombolytic therapy during CPR
has two major eﬀects. First, it can be eﬀective in acute myo-
cardial infarction (AMI) or massive pulmonary embolism
(PE), which are common causes of cardiac arrest. Second,
it may improve microcirculatory reperfusion after ROSC.
Cardiac arrest and CPR are associated with a marked activa-
tion of coagulation without adequate ﬁbrinolysis [61]. The
formation of microthrombi impairs microcirculation (“no-
reﬂow” phenomenon) and contributes to cerebral dysfunc-
tion. Thrombolytic therapy can dissolve intravascular blood
clots and improve cerebral microcirculation [62].
CPR had been considered in the past as a relative con-
traindication for thrombolysis because of the potential risk
for bleeding complications in association with chest com-
pressions. However, currently available data do not conﬁrm
the aforementioned speculation [63], and ongoing CPR is
not a contraindication to thrombolysis.
Case reports where thrombolysis was used as successful
“last resort” therapy (i.e., when the sole alternative would
be CPR termination [64]) were followed by several studies
suggesting that thrombolysis during CPR beneﬁts patients
with pulmonary embolism, or acute myocardial infarction,
or those who had been unresponsive to conventional resus-
citation eﬀorts [65–72].
Conversely, two large clinical trials failed to show any
beneﬁt in outcome with ﬁbrinolytic therapy during CPR
[73, 74].
Abu-Laban et al. [73] conducted a randomized, double-
blind, placebo-controlled trial on out-of-hospital thrombol-
ysisduringcardiacarrest.StudyparticipantshadPEA,andin
more than one-third of them the collapse was unwitnessed.6 Emergency Medicine International
The authors found no evidence of thrombolysis beneﬁt. The
study was criticized mainly for its limited statistical power.
A multicenter European study [74] investigated whether
thrombolysis with the use of tenecteplase during CPR im-
proves survival in witnessed out-of-hospital cardiac arrest of
presumed cardiac origin. The results showed no improve-
ment in survival. Despite these negative results, the authors
argued that their ﬁndings do not suggest that thrombolysis
should be withheld in patients with cardiac arrest, if the pri-
mary pathologic condition is known to be responsive to such
treatment.
Thrombolytic therapy should not be routinely used in
cardiac arrest (Class III, LOE B). The administration of
thrombolytic therapy may be considered on an “empirical
basis,” when pulmonary embolism is presumed or known
to be the cause of cardiac arrest (Class IIa, LOE B). In such
cases,CPRshouldbeperformedforatleast60–90minbefore
ending the resuscitation attempts [63, 75].
4.5. Corticosteroids. Relative to other stress states, cardiac
arrest is associated with lower cortisol levels during and after
CPR [76, 77]. This adrenocortical dysfunction results in hy-
potension and shock.
“Postresuscitation disease,” ﬁrst described by Negovsky
[78], shares common features with sepsis such as reversible
myocardial dysfunction, vasodilatation, coagulopathy, and
plasma cytokine elevation [76].
Glucocorticoids modulate vascular reactivity to cate-
cholamines[79,80]anddecreasetheproductionofvasodila-
tors such as nitric oxide [81].
Most studies suggest that serum cortisol levels are higher
in survivors of cardiac arrest [82] and low serum cortisol
levels are associated with early postresuscitation mortality
[83, 84].
In a prospective, nonrandomized, open-labeled clinical
trial, patients receiving hydrocortisone during resuscitation
had a signiﬁcantly higher ROSC rate than those receiving
placebo. In this study there was no signiﬁcant diﬀerence be-
tween the two groups in terms of short-term survival and
hospital discharge [85].
In a prospective, randomized, double-blind, placebo-
controlled trial, the combination of vasopressin-epineph-
rine-methylprednisolone during CPR followed by hydrocor-
tisone,whenpost-ROSCshockwaspresent,wascomparedto
epinephrine and placebo. The authors concluded that com-
bination therapy increased ROSC and survival to hospital
discharge [35].
Further studies are needed to investigate the eﬀect of cor-
ticosteroid supplementation during and after CPR in order
to cover some knowledge gaps in this ﬁeld.
5. Conclusion
For CPR, we emphasize the importance of high-quality chest
compressions (rate, depth, recoil), with minimum inter-
ruptions and early deﬁbrillation when appropriate. In any
case, drug delivery should not cause signiﬁcant interruptions
in these interventions.
No drug has been deﬁnitively shown to improve survival
tohospitaldischargeaftercardiacarrest.However,evaluation
of drugs is diﬃcult after prolonged ischemia time, which
anyway minimizes the probability of survival. Future studies
mightbeneﬁtfromapplyinganupperlimitforthetimefrom
collapse to the administration of drugs (e.g., 5–10min), in
order to avoid the inclusion of potentially “futile cases.”
Adrenaline remains the drug of choice during cardiac
resuscitation and other drugs such as atropine, sodium bi-
carbonate, calcium, magnesium and ﬁbrinolytic drugs may
be considered only in speciﬁc circumstances.
Corticosteroids during and after CPR seem to confer
beneﬁts with respect to hemodynamics, intensity of post-
resuscitationsystemicinﬂammatoryresponseandorgandys-
function.
Further studies are needed to investigate the eﬀect of cor-
ticosteroid supplementation during and after CPR and the
eﬀect of the combination of adrenaline and vasopressin dur-
ing cardiac resuscitation in order to cover some knowledge
gaps in the ﬁeld.
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